Dealer gets 19 years in prison for providing drugs that killed prominent NYC transgender activist
Michael Kuilan, 45, of Brooklyn, was also ordered to pay $24,482 in restitution and forfeit $30,000 and a seized firearm.
'Cecilia Gentili was tragically poisoned from fentanyl-laced heroin,' U.S. Attorney for the Eastern District of New York Joseph Nocella said in a statement. 'Today, the perpetrators who sold the deadly drugs to Gentili are being held accountable.'
Kuilan had three prior state felony convictions related to selling heroin before he pleaded guilty to the federal charges last year, according to prosecutors.
He faced up to 20 years in prison for the drug distribution charge and up to 35 years for unlawful possession of a firearm as a felon at his sentencing in Brooklyn federal court.
Kuilan's lawyer didn't immediately respond to an email seeking comment.
His co-defendant, Antonio Venti, 53, of Long Island, was sentenced in February to five years in federal prison after also pleading guilty to the same drug offense last year.
Prosecutors said text messages, cell site data, and other evidence showed that Kuilan had supplied Venti with drugs that he then sold to Gentili.
The 52-year-old Brooklyn resident was found dead in her bedroom from the combined effect of fentanyl, heroin, xylazine and cocaine on Feb. 6, 2024 — the day after purchasing the drugs, according to prosecutors.
The former sex worker had been a leading advocate for other transgender people, as well as sex workers and people with HIV.
She also acted in the FX television series 'Pose,' about the underground ballroom dance scene in the 1980s and 1990s.
Gentili's well-attended funeral at St. Patrick's Cathedral in Manhattan drew outrage from some in the Catholic community, including from the venerable church's own pastor.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
7 minutes ago
- The Independent
Trump swears he's hearing ‘great reviews' after White House Rose Garden leveled
President Donald Trump has insisted he is hearing 'great reviews' for his makeover of the White House Rose Garden, which has seen its famous manicured lawn paved over to make way for a stone patio. 'We're getting great reviews of the Rose Garden, and we had to do it,' the president told reporters on Sunday as he returned to Washington, D.C. 'When we had a press conference, you'd sink into the mud. It was grass and it was very wet, always wet and damp and wet and if it rained it would take three, four, five days to dry out and we couldn't use it really for the intended purpose. 'It's a beautiful white stone and it's a stone that's the same color as the White House itself. And because it's very white, it's going to reflect the heat and it's not going to be very hot. Yeah, we've got great reviews of the Rose Garden.' The president's assessment does not match that of social media users, who complained over the weekend that he had turned a cherished piece of American history into a 'parking lot' and a 'concrete jungle' that looks 'devoid of life.' The garden was first opened in 1913, was planted up with roses by then-first lady Jackie Kennedy in the early 1960s and has hosted receptions for visiting dignitaries for decades, also serving as a venue for annual ceremonies like the Thanksgiving turkey pardon and occasional policy announcements, most recently Trump's swiftly-reversed 'Liberation Day' tariff unveiling in April. The redesign leaves its signature rose bushes pushed to the periphery to accommodate a design much closer to the president's Mar-a-Lago home in Palm Beach, Florida. The cost of the 'upgrade' has not been released although it is known that the work was paid for by the Trust for the National Mall, a nonpartisan nonprofit that has raised $75m in private funding for D.C. restoration projects since 2007. The president has enjoyed imposing his idiosyncratic taste on 1600 Pennsylvania Avenue since returning to office and last week announced the construction of a new $200m ballroom. He has already had the Oval Office redecorated, wasting no time in switching the pictures, busts and ornaments around and introducing as much gold as possible. As CNN noted earlier this year: 'There is gold everywhere: new gold vermeil figurines on the mantle and medallions on the fireplace, gold eagles on the side tables, gilded Rococo mirrors on the doors, and, nestled in the pediments above the doorways, diminutive gold cherubs shipped in from Mar-a-Lago.' Trump also tripled the number of pictures of his predecessors on the walls, adding portraits of George Washington, Abraham Lincoln, Franklin D Roosevelt, Thomas Jefferson and Ronald Reagan, amongst others. He further reinstated his signature Diet Coke button on the Resolute Desk and a bust of Sir Winston Churchill last seen during his first term.
.jpg%3Ftrim%3D0%2C0%2C0%2C0%26width%3D1200%26height%3D800%26crop%3D1200%3A800&w=3840&q=100)
The Independent
7 minutes ago
- The Independent
Why Musk's $29bn Tesla payout is a blessing in disguise
It is commonly believed that Elon Musk owns the Tesla car company. He doesn't. First, Musk only owns about 16 per cent of the company's shares – even with the approximately $29bn additional share allocation he's just received – so he is actually a minority shareholder. Second, Tesla isn't strictly a car company, even though it obviously makes them. It is principally a tech company, and its valuation and business model is radically different, and based on its lead on autonomous or self-driving transportation. Only recently Tesla boasted that a customer in Austin, Texas had their Model Y delivered to them directly from the assembly line, with the car driving itself for the half-hour trip. Tesla is built on self-driving technology, and that, in turn, is predicated on the continuing genius of Elon Reeve Musk. So that explains a lot about this headline-grabbing story about his '$29bn pay packet'. Such an outrageous package was proposed for and by Musk some years ago but, in the objections of some shareholders, a court ruled it out. It actually amounted to some $50bn in 2018, but times change and it seems Musk and his company has been devalued by his more recent adventures in Magaland. In any case, a more ingenious method of turning capital into income was devised so that the richest person in the world could be just that little bit more loaded. Before the share deal, he was worth around $400bn, so he's going to be a bit less than 10 per cent better off once the new shares have been sorted out. Enough to rub along. This story, then, tells us a few things about Musk and Tesla. It certainly seems to be a further signal that he is moving away from politics and back to business. The Doge episode and the association with Donald Trump didn't serve him or his business interests well. Contrary to hopes/fears that having him hanging around the Oval Office and Mar-a-Lago as 'First Buddy' would lead to some lucrative government contracts, now Trump is threatening to cut him off – especially bad news for SpaceX. Musk has also gone a bit quiet about the 'America Party' he has been planning to block Trump's ruinous budget by winning key seats in Congress in elections next year. Maybe Musk will press on with that, but it seems less likely he'll do much more than provide lavish funding. It's just as well. The Doge project, for all the hype, is over, and it may have done more harm than good to the wellbeing of the American people and, undeniably, the wider world in destroying the US international aid agency. The ill-advised salutes, the nutty tweets (as some of us still insist on calling them), and all the whooping about at the Trump rallies made Musk look more idiotic than evil, and were a grievous distraction. Not even he was able to help run the US, SpaceX, Tesla and whatever else is going on simultaneously. popular at those Trump-Musk rallies – goes, 'You Can't Always Get What You Want'.
Reuters
7 minutes ago
- Reuters
Pfizer raises annual profit forecast
Aug 5 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab raised its full-year profit forecast on Tuesday after reporting better-than-expected results for the second quarter, boosted by strong demand for its heart disease drug, Vyndaqel, and blood thinner, Eliquis. The drugmaker now expects to earn $2.90 to $3.10 per share on an adjusted basis in 2025, compared with its previous expectations of $2.80 to $3.00 per share. Shares of the drugmaker rose 2.4% in premarket hours. Pfizer said the new forecast includes an impact of 20 cents per share related to its recent licensing deal with China's 3SBio ( opens new tab for experimental cancer treatment. Pfizer's results come at a time when the pharmaceutical industry is under pressure from President Donald Trump's administration to lower drug prices and is gearing up for 15% tariffs on imports from the European Union. The drugmaker has said it had enough manufacturing capacity across its 10 sites in the United States to mitigate any impact from tariffs and is open to shifting some production to these existing facilities. Investors are also closely monitoring potential disruptions to Pfizer and other companies' vaccine portfolio from policy changes under RFK Jr., a known vaccine skeptic. Vaccines account for about 20% of Pfizer's revenues. On an adjusted basis, Pfizer earned 78 cents per share in the second quarter, compared with analysts' expectations of 58 cents per share, according to LSEG data.
